Back to Browse Journals » Nature and Science of Sleep » Volume 2

Ready for takeoff? A critical review of armodafinil and modafinil for the treatment of sleepiness associated with jet lag

Authors David E McCarty

Published Date May 2010 Volume 2010:2 Pages 85—94

DOI http://dx.doi.org/10.2147/NSS.S6680

Published 17 May 2010

David E McCarty

Sleep Medicine Program, Department of Neurology, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
Abstract: Jet lag syndrome (JLS) is a clinical syndrome of disrupted nocturnal sleep and daytime neurocognitive impairment which occurs in the context of rapid transmeridian travel. Many strategies for treatment of JLS exist, and include hypnotics to enhance nocturnal sleep, chronotherapeutic approaches (eg, light therapy, melatonin, or gradual schedule shifting), and alerting agents to counter daytime sleepiness. Safety concerns have prompted renewed interest in managing JLS-associated excessive daytime sleepiness (JLSAEDS). Off-label use of the newer alerting agents modafinil and armodafinil is increasing for this indication, often at the specific request of patients. In order to better evaluate the potential risks and benefits of these medications for the management of JLSAEDS, clinicians must be aware of what is known – and still not known. In this article, the pharmacology and pharmacokinetics of modafinil and armodafinil are reviewed, along with evidence for their efficacy in treating sleepiness associated with narcolepsy, obstructive sleep apnea and shift work sleep disorder. Clinical trial data for use of alerting agents in the management of JLSAEDS are limited to one three-day trial involving armodafinil, dosed in the morning to treat JLSAEDS in the setting of eastbound transmeridian travel. This study showed improvement in objective measures of daytime sleepiness at doses of 50 and 150 mg per day. However, global impression of clinical severity of symptom scores only improved on day 1 for those patients receiving 150 mg, and were otherwise not superior to placebo. Consideration for the use of modafinil or armodafinil for the treatment of sleepiness associated with JLS involves careful integration of patient-reported goals, a review of medical contraindications, and an awareness of rare adverse events. More research is needed in order to identify those who are most likely to benefit from this intervention and better define the risk-benefit ratio for this indication.


Keywords: jet lag syndrome, modafinil, armodafinil
 

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Nonspecific pain is a marker for hypovitaminosis D in patients undergoing evaluation for sleep disorders: a pilot study

McCarty DE, Reddy A, Keigley Q, Kim PY, Cohen S, Marino AA

Nature and Science of Sleep 2013, 5:37-42

Published Date: 9 March 2013

Readers of this article also read:

Bevacizumab for the treatment of a complicated posterior melanocytoma

Urrets-Zavalia JA, Crim N, Esposito E, Correa L, Gonzalez-Castellanos ME, Martinez D

Clinical Ophthalmology 2015, 9:455-459

Published Date: 6 March 2015

Is cochlear implantation a good treatment method for profoundly deafened elderly?

Lachowska M, Pastuszka A, Glinka P, Niemczyk K

Clinical Interventions in Aging 2013, 8:1339-1346

Published Date: 2 October 2013

Nonspecific pain is a marker for hypovitaminosis D in patients undergoing evaluation for sleep disorders: a pilot study

McCarty DE, Reddy A, Keigley Q, Kim PY, Cohen S, Marino AA

Nature and Science of Sleep 2013, 5:37-42

Published Date: 9 March 2013

Age-related changes in the joint position sense of the human hand

Kalisch T, Kattenstroth JC, Kowalewski R, Tegenthoff M, Dinse HR

Clinical Interventions in Aging 2012, 7:499-507

Published Date: 22 November 2012

Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surface-functionalized with anti-Her2 trastuzumab

Yousefpour P, Atyabi F, Vasheghani-Farahani E, Mousavi Movahedi AA, Dinarvand R

International Journal of Nanomedicine 2011, 6:1977-1990

Published Date: 14 September 2011

Complexing proteins in botulinum toxin type A drugs: a help or a hindrance?

Jürgen Frevert, Dirk Dressler

Biologics: Targets and Therapy 2010, 4:325-332

Published Date: 9 December 2010

Jet lag syndrome: circadian organization, pathophysiology, and management strategies

Andrew M Vosko, Christopher S Colwell, Alon Y Avidan

Nature and Science of Sleep 2010, 2:187-198

Published Date: 19 August 2010

Management of insomnia: update and new approaches

Thomas Unbehaun, Kai Spiegelhalder, Verena Hirscher, et al

Nature and Science of Sleep 2010, 2:127-138

Published Date: 28 July 2010

Estrogen-related and other disease diagnoses preceding Parkinson’s disease

Jeanne C Latourelle, Merete Dybdahl, Anita L Destefano, et al

Clinical Epidemiology 2010, 2:153-170

Published Date: 27 May 2010

The association between insomnia and cardiovascular diseases

Kai Spiegelhalder, Cathy Scholtes, Dieter Riemann

Nature and Science of Sleep 2010, 2:71-78

Published Date: 4 May 2010